Kazia Therapeutics (Nasdaq: KZIA) shifts to kaziatx.com in ADS update

Rhea-AI Filing Summary

KAZIA THERAPEUTICS LTD (KZIA) filed a prospectus supplement to its Form F-1 registration statement describing an offering of 232,956 American Depositary Shares (ADSs), representing 116,478,000 ordinary shares

The attached Form 6-K reports that on August 28, 2026, Kazia launched a new corporate website at www.kaziatx.com, replacing prior references to www.kaziatherapeutics.com. The company states the site is intended to improve access to information on its business, products, services, clinical trials, and corporate developments. The Form 6-K is also incorporated by reference into three existing Form F-3 registration statements.

Key Figures

ADSs registered: 232,956 American Depositary Shares Ordinary shares represented: 116,478,000 ordinary shares ADS last reported sale price: $13.58 per ADS +1 more

4 metrics

ADSs registered 232,956 American Depositary Shares Described on the prospectus supplement cover

Ordinary shares represented 116,478,000 ordinary shares Each ADS represents a number of ordinary shares as stated

ADS last reported sale price $13.58 per ADS Last reported sale price on Nasdaq on August 28, 2026

Form F-3 file numbers 333-276091; 333-281937; 333-294392 Registration statements into which the Form 6-K is incorporated by reference

Key Terms

American Depositary Shares, Nasdaq Capital Market, Form 6-K, foreign private issuer, +1 more

5 terms

American Depositary Shares financial

"232,956 American Depositary Shares representing 116,478,000 Ordinary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Nasdaq Capital Market financial

"The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”)"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

Form 6-K regulatory

"current report on Form 6-K, furnished to the Securities and Exchange Commission"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

incorporates by reference regulatory

"The Company hereby incorporates by reference the information contained herein"

Offering Details

secondary

Offering

Offering Type secondary

FAQ

What does Kazia Therapeutics (KZIA) register in this prospectus supplement?

Kazia Therapeutics updates its Form F-1 registration statement covering 232,956 ADSs representing 116,478,000 ordinary shares, by incorporating information from a new Form 6-K. The economic and structural terms of the registered securities are set in the underlying prospectus.

What new disclosure does KZIA add through the attached Form 6-K?

Kazia discloses that on August 28, 2026 it launched a new corporate website at www.kaziatx.com. All prior references to www.kaziatherapeutics.com in its SEC filings should now be read as referring to this new URL, where it posts business and clinical information.

How is the new Form 6-K used in Kazia Therapeutics’ (KZIA) registrations?

The company incorporates the Form 6-K, which describes the new website, by reference into its Form F-1 prospectus and into three Form F-3 registration statements with file numbers 333-276091, 333-281937, and 333-294392.

On which market are KZIA’s ADSs listed and what was the recent price?

Kazia’s ADSs are listed on The Nasdaq Capital Market under the symbol KZIA. On August 28, 2026, the last reported sale price of the ADSs on Nasdaq was $13.58 per ADS.

Does the KZIA prospectus supplement mention investment risks?

Yes. It states that investing in the company’s securities involves a high degree of risk and directs readers to the “Risk Factors” section of the main prospectus and to risk factors in the most recent Form 20-F and other reports incorporated by reference.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 07:36 AM Accepted by SEC EDGAR 08/31/2026 - 07:33 AM Learn about SEC filing dates

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-290598

PROSPECTUS SUPPLEMENT

(to Prospectus dated December 23, 2025)

232,956 American Depositary Shares representing

116,478,000

Ordinary Shares

Kazia Therapeutics Limited

This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-290598), as amended, with the information contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on August 31, 2026 (the “August 31, 2026 Form 6-K”). Accordingly, we have attached the August 31, 2026 Form 6-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On August 28, 2026, the last reported sale price of the ADSs on Nasdaq was $13.58 per ADS.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 9 of the Prospectus and the “Risk Factors” in “Item 3. Key Information-D. Risk Factors” of our most recent Annual Report on Form 20-F, which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is August 31, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 000-29962

Kazia Therapeutics Limited.

(Exact Name of Registrant as Specified in Its Charter)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On August 28, 2026, Kazia Therapeutics Limited (the “Company”) launched a new website. The new website can be found at www.kaziatx.com.

Any prior references to the Company’s website, including references to www.kaziatherapeutics.com, in the Company’s filings with the Securities Exchange Commission (the “SEC”) should be read to refer to the new URL, www.kaziatx.com, as applicable.

The new website has been designed to provide investors, customers, and other stakeholders with enhanced access to information regarding the Company’s business, products, services, clinical trials, and corporate developments. We encourage investors, patients, business partners, researchers, and other stakeholders to review the information we post on our website, in addition to following our press releases and SEC filings.

Incorporation by Reference

The Company hereby incorporates by reference the information contained herein into the Company’s registration statements on Form F-3 (File Nos. 333-276091, 333-281937 and 333-294392).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Kazia Therapeutics Limited.
Date: August 31, 2026	By:	/s/ John Friend
	Name:	John Friend
	Title:	Chief Executive Officer

2